NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
NHS England · £4,108,145,000 · closes 7 Apr 2025
£4,108,145,000
Estimated value
Closed
Deadline
17 Feb 2025
Published
This tender has closed.
See what's open in medical equipment and pharmaceuticals, or get contracts like this in your inbox each morning — free.
About this contract
NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/><br/>CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines – Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/><br/>CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines – Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026
Key dates
Source
Lots — bid on the ones that fit
This contract is split into lots. You can usually bid for just the ones that suit your firm.
Who to contact
Similar open tenders
Contains public sector information licensed under OGL v3.0